---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021556"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:46:30.284317+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics Q3 net loss $41.4M; Phase 1/2 trials for DM1 and DMD underway with data H2 2023

## Summary
- Net loss of $41.4M ($0.80 per share) vs $42.6M ($0.83) in Q3 2021; cash $248.1M funds operations through 2024.
- R&D expense $34.7M, G&A $7.6M; R&D slightly down YoY.
- ACHIEVE trial (DYNE-101 for DM1) and DELIVER trial (DYNE-251 for DMD) both enrolling; primary endpoints safety and tolerability.
- DYNE-251 granted FDA Fast Track designation in October 2022.
- Data from placebo-controlled portions of both trials anticipated in second half of 2023.

## SEC filing metadata
- accession: 0000950170-22-021556
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017022021556/0000950170-22-021556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017022021556/dyn-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021556
- JSON: https://secwatch.observer/filing/0000950170-22-021556.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021556.txt

## Key facts
- Earnings Releases
  Dyne Therapeutics, Inc. reported the third quarter of 2022 results: net income Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share., EPS $0.80 per basic and diluted share.
  - Period: the third quarter of 2022
  - Net income: Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share.
  - EPS: $0.80 per basic and diluted share
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017022021556/0000950170-22-021556-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.